Latest MedImmune Inc. Stories
MENLO PARK, Calif., July 20 /PRNewswire/ -- 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. "We are very pleased to welcome Jim Young to the 3-V Board," said David M. Mott, 3-V's Executive Chairman.
MENLO PARK, Calif., June 3 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Edward M.
ATLANTA, April 19 /PRNewswire/ -- MedImmune announced today it will present 10 abstracts at the National Immunization Conference (NIC), all of which add to the company's growing body of research regarding pediatric infectious disease prevention.
PHILADELPHIA, Oct. 30 /PRNewswire/ -- MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009.
INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
PLYMOUTH MEETING, Pa., Oct. 29 /PRNewswire-FirstCall/ -- Genaera Corporation today reported that development partner MedImmune, Inc.
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue.
BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus).
- A volcanic mudflow.